The global bacteriophage therapy market is witnessing significant growth due to increasing prevalence of antibiotic-resistant bacterial infections. Bacteriophages or bacterial viruses are viruses that infect and replicate inside bacteria. They can be used to treat pathogenic bacterial infections and have gained increasing attention as an alternative to conventional antibiotics due to the emergence of multi-drug resistant bacteria. Bacteriophage therapy involves the use of lytic bacteriophages to infect and destroy specific pathogenic bacterial strains without harming other bacteria in the human microflora. It is highly specific and effective against the targeted bacterial strain. The ability of bacteriophages to self-replicate at the site of infection also increases their effectiveness as they multiply until all the host bacteria are destroyed.

The Global bacteriophage therapy market is estimated to be valued at US$ 50.24 Bn in 2024 and is expected to exhibit a CAGR of 24% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the bacteriophage therapy market are General Dynamics, Airbus, Nordam, Saint-Gobain, Meggitt, Starwin Industries, Kitsap Composites, Orbital ATK, Jenoptik, Harris, Vermont Composites, Pacific Radomes, Royal Engineered Composites, AVIC, ATK, Kelvin Hughes, Raytheon, Leonardo, Ducommun, CPI. These players are focusing on new product launches and strategic collaborations to expand their share in the market.

The emergence of antibiotic-resistant bacteria along with the increasing prevalence of various bacterial infections is anticipated to offer significant growth opportunities to bacteriophage therapy manufacturers over the forecast period. The demand for alternative treatment options for bacterial infections is expected to drive the adoption of bacteriophage therapy globally.

European countries, especially the UK, France, Germany and Russia, have widely accepted bacteriophage therapy and registered phage therapeutic products. Companies are expanding their operations in Europe to leverage its large addressable market. Manufacturers are also focusing on countries in Asia Pacific and Latin America for further expansion owing to limited availability of antibiotics in these regions.

Market Drivers
Growing global threat of antimicrobial resistance - Increasing prevalence of antimicrobial resistance due to overuse and misuse of conventional antibiotics is a major driver for the Bacteriophage Therapy Market Growth. Phages are considered viable alternatives to treat antibiotic-resistant infections.
Efficacy against biofilms - Bacteriophages are highly effective against bacterial biofilms formed on medical devices, prostheses and tissues, making them suitable for a wide array of clinical applications.

Market Restraints
Limited understanding of phage biology - Complex nature of interactions between phages and host bacteria needs deeper understanding to ensure safety, efficacy and quality of phage therapeutics.
Stringent regulatory framework - Regulatory requirements for phage therapeutics differ in various regions. Obtaining approvals and conducting clinical trials is a long and costly process hampering market growth.